Danaher Co. (NYSE:DHR) Shares Purchased by Cambridge Trust Co.

Cambridge Trust Co. boosted its holdings in Danaher Co. (NYSE:DHR) by 1.7% in the 4th quarter, HoldingsChannel.com reports. The firm owned 74,438 shares of the conglomerate’s stock after buying an additional 1,233 shares during the quarter. Cambridge Trust Co.’s holdings in Danaher were worth $17,221,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Banco Santander S.A. acquired a new position in Danaher in the third quarter valued at $683,000. First Citizens Bank & Trust Co. increased its stake in Danaher by 0.6% in the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after purchasing an additional 149 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock worth $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in Danaher by 4.8% during the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares during the last quarter. Finally, Keybank National Association OH boosted its position in shares of Danaher by 0.5% in the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after buying an additional 2,567 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Performance

DHR traded down $3.24 on Thursday, hitting $236.15. 2,674,049 shares of the stock traded hands, compared to its average volume of 2,705,003. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The firm has a market capitalization of $174.88 billion, a PE ratio of 37.46, a P/E/G ratio of 3.65 and a beta of 0.83. The business has a fifty day moving average price of $249.28 and a two-hundred day moving average price of $229.86. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.18. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The company had revenue of $6.41 billion for the quarter, compared to analyst estimates of $6.10 billion. During the same period in the prior year, the company posted $2.87 EPS. The company’s revenue was down 10.2% compared to the same quarter last year. On average, research analysts predict that Danaher Co. will post 7.62 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a $0.27 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. Barclays increased their price target on Danaher from $240.00 to $260.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 10th. JPMorgan Chase & Co. lifted their price target on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, December 20th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and lifted their price target for the company from $250.00 to $280.00 in a research report on Wednesday. Citigroup lifted their price target on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $268.27.

Insider Activity

In other news, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Daniel Raskas sold 23,757 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,957 shares of company stock worth $8,265,802. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.